Forex
World
Market
Business
Cryptocurrency
Commodities
MAP
Publish for free
Business
financetom
/
Business
/
--FTC to Sue Pharmacy Benefit Managers Over Insulin Prices, Wall Street Journal Reports
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
Forex
Stocks Market
Commodities
--FTC to Sue Pharmacy Benefit Managers Over Insulin Prices, Wall Street Journal Reports
Jul 10, 2024 11:30 AM
02:03 PM EDT, 07/10/2024 (MT Newswires) --
Price: 498.71, Change: +6.59, Percent Change: +1.34
Previous page:
Calibre's Valentine Gold Mine 2024 Exploration Program Underway; Shares Gained 5% On Tuesday
Next page:
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Release time ⇩
Release time ⇧
Like count ⇩
Show More Comments
Related Articles >
Calibre's Valentine Gold Mine 2024 Exploration Program Underway; Shares Gained 5% On Tuesday
Apr 3, 2024
07:10 AM EDT, 04/03/2024 (MT Newswires) -- Calibre Mining Corp. ( CXBMF ) , which gained more than 5% yesterday, on Wednesday said its 2024 exploration program at the Valentine gold mine in Newfoundland and Labrador is underway. According to a statement, the property hosts five gold deposits with measured and indicated resources of 4.0 million ounces and inferred resources...
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
Apr 3, 2024
April 3 (Reuters) - Lenz Therapeutics ( LENZ ) said on Wednesday its experimental drugs to treat loss of near vision met the main goal of a late-stage study. ...
Digihost Technology Reports Loss for Q4, Revenue Grows; Provides Update
Apr 3, 2024
07:08 AM EDT, 04/03/2024 (MT Newswires) -- Digihost Technology Inc. ( DGHI ) , a US-based blockchain technology and computer infrastructure company, on Wednesday reported a fourth-quarter net loss of US$9.7 million, or US$0.34 per diluted share, as compared with a loss of US$9.7 million, or US$0.36 per diluted share, a year earlier. Revenue for the quarter ended Dec. 31,...
Cancer biotech firm Alterome Therapeutics raises $132 mln in Goldman Sachs-led round
Apr 3, 2024
April 3 (Reuters) - Biotechnology firm Alterome Therapeutics said on Wednesday it has raised $132 million in a series B financing round, which was led by Goldman Sachs Alternatives. The series B financing, which brings its total funding to nearly $232 million to date, also saw participation by Canaan Partners, Driehaus Capital Management, Invus, Digitalis Ventures, Blue Owl Capital, and...
About
Terms and Conditions
Privacy policy
Cookie Settings
Contact Us
Services
Login
register
financetom
Market
Personal Finance
Business
Economy
Cryptocurrency
MAP
Links
zpostcode
Recruit
weather
mreligion
Yellowpages
sport
constellation
shopping
name
game
directory
literature
Word
tour
furnish
Lottery
tftnews
lyrics
News
digital
car
dir
Edu
Finance
Copyright 2023-2026 -
www.financetom.com
All Rights Reserved
News
World
Market
Environment
Technology
Personal Finance
Politics
Retail
Business
Economy
Cryptocurrency
MAP